Neuroimaging biomarkers for Parkinson disease: Facts and fantasy

Annals of Neurology

Volumn 76, Issue 6, 2014, Pages 769-783

  Perlmutter, Joel S ^a   Norris, Scott A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPAMINE F 18; BIOLOGICAL MARKER;

ARTICLE; AUTOPSY; COGNITIVE DEFECT; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; HUMAN; MOLECULAR IMAGING; NEUROIMAGING; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; SUBSTANTIA NIGRA; BRAIN; COGNITION DISORDERS; METABOLISM; PATHOLOGY; PROCEDURES; PSYCHOLOGY; STANDARDS;

BIOLOGICAL MARKERS; BRAIN; COGNITION DISORDERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; NEUROIMAGING; PARKINSON DISEASE;

EID: 84913582942     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24291     Document Type: Article

References (80)

1. Bagchi DP, Yu L, Perlmutter JS, et al. Binding of the radioligand SIL23 to alpha-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS One 2013;8:e55031.
2. Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 2003;184(suppl 1):S68-S79.
3. Perlmutter JS, Tempel LW, Black KJ, et al. MPTP induces dystonia and parkinsonism: clues to the pathophysiology of dystonia. Neurology 1997;49:1432-1438.
4. Burn DJ, Mark MH, Playford ED, et al. Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology 1992;42:1894-1900.
5. Nagai Y, Obayashi S, Ando K, et al. Progressive changes of preand post-synaptic dopaminergic biomarkers in conscious MPTPtreated cynomolgus monkeys measured by positron emission tomography. Synapse 2007;61:809-819.
6. Guttman M, Yong VW, Kim SU, et al. Asymptomatic striatal dopamine depletion: PET scans in unilateral MPTP monkeys. Synapse 1988;2:469-473.
7. Serrano VJ, Garcia BL, Duran BC, et al. Negative predictive value of SPECT with I123 ioflupane in movement disorders (reply) [in Spanish]. Rev Esp Med Nucl 2009;28:267-268.
8. Tabbal SD, Tian L, Karimi M, et al. Low nigrostriatal reserve for motor parkinsonism in nonhuman primates. Exp Neurol 2012;237: 355-362.
9. Karimi M, Tian L, Brown CA, et al. Validation of nigrostriatal positron emission tomography measures: critical limits. Ann Neurol 2013;73:390-396.
10. Tang CC, Poston KL, Dhawan V, et al. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci 2010;30:1049-1056.
11. Bucher HC, Guyatt GH, Cook DJ, et al. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA 1999; 282:771-778.
12. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-613.
13. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.
14. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788.
15. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. Am J Cardiol 1988;61:501-509.
16. Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005;111:2233-2240.
17. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
18. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101.
19. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005;64:208-215.
20. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006;59:459-466.
21. Dorsey ER, Holloway RG, Ravina BM. Biomarkers in Parkinson's disease. Expert Rev Neurother 2006;6:823-831.
22. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-718.
23. Pate BD, Kawamata T, Yamada T, et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 1993;34:331-338.
24. Snow BJ, Tooyama I, McGeer EG, et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34:324-330.
25. Alvarez-Fischer D, Blessmann G, Trosowski C, et al. Quantitative [(123)I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease. Neuroimage 2007;38:5-12.
26. Tabbal SD, Mink JW, Antenor JA, et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced acute transient dystonia in monkeys associated with low striatal dopamine. Neuroscience 2006;141:1281-1287.
27. Marek KL, Seibyl JP, Zoghbi SS, et al. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-237.
28. Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013;136:2419-2431.
29. Tian L, Karimi M, Loftin SK, et al. No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease. PLoS One 2012;7:e31439.
30. Tian L, Karimi M, Brown CA, et al. In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment. Brain Res 2014; 1571:49-60.
31. Brown CA, Karimi MK, Tian L, et al. Validation of midbrain positron emission tomography measures for nigrostriatal neurons in macaques. Ann Neurol 2013;74:602-610.
32. Au WL, Adams JR, Troiano AR, Stoessl AJ. Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. Brain Res Mol Brain Res 2005;134:24-33.
33. Guttman M, Stewart D, Hussey D, et al. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001;56:1559-1564.
34. Fernagut PO, Li Q, Dovero S, et al. Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTPtreated monkeys. PLoS One 2010;5:e14053.
35. Innis RB, Marek KL, Sheff K, et al. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord 1999;14:436-442.
36. Racette BA, Good L, Antenor JA, et al. [18F]FDOPA PET as an endophenotype for Parkinson's disease linkage studies. Am J Med Genet B Neuropsychiatr Genet 2006;141:245-249.
37. Racette BA, Antenor JA, McGee-Minnich L, et al. [18F]FDOPA PET and clinical features in parkinsonism due to manganism. Mov Disord 2005;20:492-496.
38. Criswell SR, Perlmutter JS, Crippin JS, et al. Reduced uptake of FDOPA PET in end-stage liver disease with elevated manganese levels. Arch Neurol 2012;69:394-397.
39. Wolters EC, Huang CC, Clark C, et al. Positron emission tomography in manganese intoxication. Ann Neurol 1989;26:647-651.
40. Otsuka M, Kuwabara Y, Ichiya Y, et al. Differentiating between multiple system atrophy and Parkinson's disease by positron emission tomography with 18F-dopa and 18F-FDG. Ann Nucl Med 1997;11:251-257.
41. Criswell SR, Perlmutter JS, Videen TO, et al. Reduced uptake of [18F]FDOPA PET in asymptomatic welders with occupational manganese exposure. Neurology 2011;76:1296-1301.
42. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298.
43. Frost JJ, Rosier AJ, Reich SG, et al. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-431.
44. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 1990;5:203-213.
45. Antonini A, Vontobel P, Psylla M, et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol 1995;52:1183-1190.
46. Ishikawa T, Dhawan V, Chaly T, et al. Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease. J Nucl Med 1996;37:216-222.
47. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of the progression in Parkinson's disease. Brain 1996;119:585-591.
48. Bohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006;26:1198-1212.
49. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
50. Sawle GV, Playford ED, Burn DJ, et al. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data. Arch Neurol 1994;51: 237-243.
51. Ceravolo R, Antonini A, Volterrani D, et al. Predictive value of nigrostriatal dysfunction in isolated tremor: a clinical and SPECT study. Mov Disord 2008;23:2049-2054.
52. Menendez-Gonzalez M, Tavares F, Zeidan N, et al. Diagnoses behind patients with hard-to-classify tremor and normal DaTSPECT: a clinical follow up study. Front Aging Neurosci 2014;6: 56.
53. Jennings DL, Seibyl JP, Oakes D, et al. (123I) beta-CIT and singlephoton emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 2004;61:1224-1229.
54. Fuente-Fernandez R. Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology 2012;78:696-701.
55. Van Laere K, Everaert L, Annemans L, et al. The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging 2008; 35:1367-1376.
56. Dodel RC, Hoffken H, Moller JC, et al. Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach. Mov Disord 2003;18(suppl 7):S52-S62.
57. Stoessl AJ. Radionuclide scanning to diagnose Parkinson disease: is it cost-effective? Nat Clin Pract Neurol 2009;5:10-11.
58. Perlmutter JS, Eidelberg D. To scan or not to scan: DaT is the question. Neurology 2012;78:688-689.
59. Takahashi H, Levine RA, Galloway MP, et al. Biochemical and fluorodopa positron emission tomographic findings in an asymptomatic carrier of the gene for dopa-responsive dystonia. Ann Neurol 1994;35:354-356.
60. O'Brien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919-925.
61. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6:305-313.
62. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 2010;289:18-22.
63. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-844.
64. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004;55:306-319.
65. Mintun MA, LaRossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452.
66. Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009;66:1469-1475.
67. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795-804.
68. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79:1331-1338.
69. Maetzler W, Liepelt I, Reimold M, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2009;34:107-112.
70. Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71:903-910.
71. Foster ER, Campbell MC, Burack MA, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord 2010;15:2516-2523.
72. Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007;62:229-234.
73. Baron JC, Farid K, Dolan E, et al. Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage. J Cereb Blood Flow Metab 2014;34:753-758.
74. Burack MA, Hartlein J, Flores HP, et al. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010;74:77-84.
75. Kotzbauer PT, Cairns NJ, Campbell MC, et al. Pathologic accumulation of alpha-synuclein and Abeta in Parkinson disease patients with dementia. Arch Neurol 2012;69:1326-1331.
76. Cairns NJ, Ikonomovic MD, Benzinger T, et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol 2009;66:1557-1562.
77. Campbell MC, Markham J, Flores H, et al. Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. Neurology 2013;81:520-527.
78. Gomperts SN, Locascio JJ, Rentz D, et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013;80:85-91.
79. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010;75:1055-1061.
80. Buddhala C, Campbell MC, Perlmutter JS, Kotzbauer PT. Correlation between decreased CSF a-synuclein and Ab1-42 in Parkinson disease. Neurobiol Aging 2014. pii: S0197-4580(14)00512-0. doi: 10.1016/j.neurobiolaging.2014.07.043. [Epub ahead of print]